Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.
about
Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus InfectionTherapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuckHepatitis B: future curative strategiesFuture Therapy for Hepatitis B Virus: Role of ImmunomodulatorsMutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infectionsA whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance.Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.Antiviral therapies and prospects for a cure of chronic hepatitis B.Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infectionPresent and future therapies of hepatitis B: From discovery to curePrime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus.Medical virology of hepatitis B: how it began and where we are nowNovel Woodchuck Hepatitis Virus (WHV) transgene mouse models show sex-dependent WHV replicative activity and development of spontaneous immune responses to WHV proteins.New therapeutic vaccination strategies for the treatment of chronic hepatitis B.Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow.Dissecting the dendritic cell controversy in chronic hepatitis B virus infection.Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?Therapeutic vaccines in HBV: lessons from HCV.Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.Immune Response in Hepatitis B Virus Infection.Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cureAdvances in therapeutics for chronic hepatitis B.The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.Prospects and progress of DNA vaccines for treating hepatitis B.Molecular cloning, characterization and expression analysis of woodchuck retinoic acid-inducible gene I.Present and future DNA vaccines for chronic hepatitis B treatment.Treatment of hepatitis B virus: an update.Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.The IL-1R/TLR signaling pathway is essential for efficient CD8(+) T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model.TLR9-Mediated Conditioning of Liver Environment Is Essential for Successful Intrahepatic Immunotherapy and Effective Memory Recall.Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models.Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccinationEnhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96.A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model.Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B.
P2860
Q26795919-14811E5A-CF9D-42AE-9A9E-90AE7DE26D10Q26828598-D4F518E3-4814-4D80-8A20-39642C4F7110Q27011623-189988FC-7CF4-494C-878E-2EFC4218E964Q28078148-9FF43B70-2110-4D2B-B07E-678477E20026Q28086907-119E0ECF-823F-4FDE-877E-8B1997B3B1B3Q33933196-59BD31DC-649B-4EA5-8308-32ECF889D195Q34409291-B943F7FC-B989-4CBF-BC80-6A31A445BD1EQ35008279-3B4AAF8F-D80B-45E7-BBB4-62839BCD0B1FQ35075107-5B5285AA-11E2-40B6-82BE-ECB03B25294EQ35082215-5BF274F3-5ECB-415C-9A0A-644F0E3120FDQ35245231-E0241753-6446-46C5-BA56-9F160D8DF8C2Q36073739-2C990280-05B9-4215-A835-6ADFDDB022F4Q36107127-F0C40C64-B524-4873-A531-E95ED3C9E30EQ36378278-17C57861-374F-47BD-A69B-BBCF12C3E73DQ36978876-0F14F116-A766-4D9B-AE6F-CA5DFA6D18FCQ37059714-6291293E-E4C0-4F6D-A3FC-A3A524D0749EQ37547342-CBC8D64E-16C8-49E2-ADF1-6140971036BBQ38180981-E5F2BF8A-857D-4143-A760-C58C98F30204Q38180983-93F92B17-A18C-405E-B919-8AFAED08E780Q38255840-7734C4D8-06B7-4518-A35B-246354D02621Q38264371-EE092952-DFC9-45AA-8E60-853E1E11360DQ38289729-7B14EA91-3426-4D3A-9A65-284AD0E8AF3EQ38312255-4C0A17F7-D1AE-41E2-AB2E-CFF85B62872AQ38351585-575BC15D-4262-4536-8273-5D6959B3A1A1Q38541811-F7962BF2-EA19-4AD0-98FE-CC085279F778Q38553065-5B5E770F-C7BF-45B0-8BD6-B4B8AB3845D6Q38585657-A8EE2018-1FAE-4A13-B419-7596716E146EQ38618869-A920C9CC-ED5C-4B41-BEB3-5EABEAEA260DQ38664504-10FD30E3-A97F-4FAD-A8F3-B7506CBAF674Q38759960-8CCB26B4-F73B-4D8F-B6EF-5170D1D43BC4Q38790065-DE14A1BB-D6D5-46CE-9779-C08FD1969486Q38794446-3BFEB590-451F-48AC-8E40-CAED4C5DC5AEQ38846017-E547DDDA-E268-4B70-AA75-2C3187159082Q40102035-B92C9E37-AADC-4CB7-A900-1A6A19BE7FA9Q40119511-1E5C234B-A6CD-4354-B978-90CE57C1BF53Q40291593-5D2E18A7-E4DB-4503-9277-8E80E5453DFAQ41607528-7BDF8258-2FE1-4E9F-8ACE-A69288770F66Q42182831-7D5C720A-1E98-4EA0-9F4D-3711C7CE35B6Q47547227-8E7E1362-1811-4430-A6BC-523AA4730A15Q47553095-2A36C27C-8D45-48B2-A024-7FD867EA8AFA
P2860
Combination of DNA prime--adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@ast
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@en
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@nl
type
label
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@ast
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@en
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@nl
prefLabel
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@ast
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@en
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@nl
P2093
P2860
P1433
P1476
Combination of DNA prime--aden ...... itis B in the woodchuck model.
@en
P2093
Anna D Kosinska
Dieter Glebe
Ejuan Zhang
Lena Johrden
Melanie Fiedler
Michael Roggendorf
Oliver Wildner
Pia L Seiz
P2860
P304
P356
10.1371/JOURNAL.PPAT.1003391
P50
P577
2013-06-13T00:00:00Z